TOPAMAX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOPAMAX (TOPAMAX).
Antiepileptic; modulates voltage-gated sodium channels, enhances GABA-A activity, antagonizes AMPA/kainate glutamate receptors, weakly inhibits carbonic anhydrase.
| Metabolism | Minimally metabolized (~20%) via hydroxylation, hydrolysis, and glucuronidation; not extensively metabolized by CYP450; ~70% excreted unchanged in urine. |
| Excretion | Renal: ~70% (unchanged drug); remainder as metabolites. Biliary/fecal: minimal (<5%). |
| Half-life | Terminal elimination half-life is 21 hours (range 18-23 hours). Linear pharmacokinetics. Half-life is prolonged in renal impairment (CrCl <70 mL/min: ~35 hours). |
| Protein binding | 15-41% bound; primarily to albumin. Binding is low and not clinically significant. |
| Volume of Distribution | 0.6-0.8 L/kg. Indicates distribution into total body water, suggesting minimal tissue binding. |
| Bioavailability | Oral: ~80% (range 65-95%). Bioavailability is not affected by food. Tablets and sprinkle capsules are bioequivalent. |
| Onset of Action | Oral: Peak plasma concentrations achieved in 2-4 hours. Clinical onset of anticonvulsant effect typically within 1-2 weeks of dosing. |
| Duration of Action | Duration of anticonvulsant effect: ~24 hours with twice-daily dosing due to half-life. For migraine prophylaxis, therapeutic effect may take 2-4 weeks to manifest. |
| Molecular Weight | 339.37 |
Initial dose 25 mg orally twice daily; titrate by 25-50 mg weekly to effective dose; usual maintenance dose 200-400 mg/day divided twice daily; maximum 1600 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | CrCl ≥70 mL/min: no adjustment. CrCl 30-69 mL/min: reduce dose by 50%. CrCl <30 mL/min: reduce dose by 75%. Hemodialysis: administer 50% supplemental dose after dialysis. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: reduce dose by 75%. |
| Pediatric use | For epilepsy (age 2-16): initial dose 1-3 mg/kg/day divided twice daily; titrate by 1-3 mg/kg/day every 1-2 weeks; maintenance typically 5-9 mg/kg/day divided twice daily. For migraine prophylaxis (age 12-17): initial 25 mg/day at bedtime; titrate to 50-100 mg/day divided twice daily. |
| Geriatric use | Initiate at lower dose (25 mg daily); titrate slowly due to increased sensitivity and higher risk of adverse effects; monitor renal function and adjust based on CrCl; consider reduced target doses. |
| 1st trimester | Topiramate is associated with increased risk of oral clefts and other congenital malformations when used during first trimester. Exposure increases risk of cleft lip/palate by 2-20 fold compared to unexposed. Use only if benefit justifies risk. |
| 2nd trimester | Topiramate may cause fetal growth restriction and oligohydramnios. Monitor fetal growth and amniotic fluid volume. Consider dose reduction if possible. |
| 3rd trimester | Topiramate exposure can cause neonatal withdrawal symptoms (irritability, jitteriness, poor feeding) and metabolic acidosis. Taper if discontinuing. Monitor neonate for signs of withdrawal. |
Clinical note
Comprehensive clinical and safety monograph for TOPAMAX (TOPAMAX).
| Placental transfer | Topiramate crosses the placenta readily with cord blood levels similar to maternal serum. Fetal exposure is substantial. |
| Breastfeeding | Topiramate is excreted into breast milk in moderate amounts (milk/plasma ratio ~0.86). Infant serum levels are low (2–10% of maternal weight-adjusted dose). Monitor infant for sedation, diarrhea, poor suckling. Use with caution, especially in neonates or preterm infants. |
■ FDA Black Box Warning
Acute myopia and secondary angle-closure glaucoma; oligohidrosis and hyperthermia; metabolic acidosis; fetal risk (pregnancy category D).
| Serious Effects |
Hypersensitivity to topiramate or any component of formulationMetabolic acidosis (acute or chronic) unless treated and monitoredConcomitant use with carbonic anhydrase inhibitors (e.g., acetazolamide) due to increased risk of metabolic acidosis and nephrolithiasis
| Precautions | Monitor for oligohidrosis and hyperthermia; monitor for metabolic acidosis (measure serum bicarbonate); avoid abrupt discontinuation (seizure frequency increase); nephrolithiasis risk; acute myopia and secondary angle-closure glaucoma; cognitive/neuropsychiatric adverse events; teratogenicity (cleft lip/palate); decreased efficacy of oral contraceptives; hyperammonemia with encephalopathy with valproic acid use; ketoacidosis risk. |
| Food/Dietary | Avoid grapefruit juice as it may increase drug levels; maintain adequate hydration to reduce risk of kidney stones; high-fat meals may delay absorption. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category D. First trimester exposure increases risk of oral clefts (6- to 16-fold). Second/third trimester exposure associated with low birth weight, microcephaly, and developmental delay. Risk of major congenital malformations 3-5% vs 1-2% baseline. |
| Fetal Monitoring | Monitor fetal growth via serial ultrasounds. Consider amniocentesis for oral clefts if first trimester exposure. Assess infant for cleft palate at birth. Monitor maternal serum topiramate levels (therapeutic range 5-20 mcg/mL) and adjust dose for efficacy and toxicity. |
| Fertility Effects | No known impairment of fertility in females; may cause menstrual irregularities. In males, no documented effect on spermatogenesis or fertility. Use effective contraception due to teratogenicity. |
| Clinical Pearls | Titrate slowly to minimize cognitive side effects; monitor serum bicarbonate for metabolic acidosis; risk of acute angle-closure glaucoma; contraindicated in pregnancy; dose adjustment needed in renal impairment. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · Drink plenty of fluids to prevent kidney stones. · Report vision changes, eye pain, or sudden confusion immediately. · Avoid alcohol as it may worsen side effects. · Use effective contraception; this drug can harm an unborn baby. · May cause dizziness or drowsiness; avoid driving until you know how it affects you. |